Inflammation and Immunity
Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Carolyn Cuff, Ph.D., Janssen (Co-Chair)

David Fox, M.D., University of Michigan (Co-Chair)

Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics

Tara Altepeter, M.D., FDA/CDER

Niyanna Barron, M.B.A., OLINK

Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S

Robert Benschop, Ph.D., Eli Lilly

Maria Bettinotti, Ph.D., Association of Molecular Pathology (AMP)

Jonathan Blackburn, Ph.D., Sengenics

Alex Blasky, Ph.D., SomaLogic

Mathias Blom, M.D., Ph.D., Rhino Health

Preethi Chander, Ph.D., NIDCR/NIH

Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation

Chao Jiang, Ph.D., NIAID/NIH

Kelly Chun, Ph.D., LabCorp

Sahar Dawisha, M.D., FDA/CDRH

Betty Diamond, Ph.D., Feinstein Institute

Renee Donahue, Ph.D., NIH/NCI

Thomas Fuerst, Ph.D., BioClinica

Heath Guay, Ph.D., AbbVie

Mireia Guerau, PharmD, PhD – NIH / NIAID

Kathy Hammitt, M.A., Sjogren’s Foundation

Caren Heller, M.D., MBA, Crohn’s & Colitis Foundation of America

Andrea Hooper, Ph.D, Regeneron

Julie Huang, Ph.D., Alector

Robert Iannone, M.D., Jazz Pharmaceuticals

Kathy Jung, Ph.D., NIH/NIAA

Ernst Kriehuber, M.D., UCB

David Martin, M.D., Pfizer

Afsaneh Mozaffarian, Gilead

Bruce McManus, M.D., Ph.D., University of British Columbia

Sumanta Mukherjee, Ph.D., GlaxoSmithKline

Maik Muller, Ph.D., Biognosys

Nikolay Nikolov, M.D., FDA/CDER

Mariaelena Occhipinti, M.D., Ph.D., Radiomics

Heiyoung Park, Ph.D., NIAMS/NIH

Jane Parnes, M.D., Amgen

Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis

Barbara Radziszewska, Ph.D., M.P.H., NIH/NIA

John Reveille, M.D., University of Texas Health Science Center (Houston)

Lisa Rider, M.D., NIH/NIEHS

Jonathan Robbins, M.D., Ph.D., Merck

Jane Salmon, M.D., Hospital for Special Surgery

Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research

Susana A. Serrate-Sztein, M.D., NIH/NIAMS

Glennda Smithson, Ph.D., Takeda

Lisa Spain, Ph.D., NIH / NIDDK

Emily Boyd Stormoen, Arthritis National Research Foundation

Michael Townsend, Ph.D., Genentech

Maria Vassileva, Ph.D., Arthritis Foundation

Sudha Visvanathan, Ph.D., Boehringer Ingelheim

Andrea Wagenfeld, Ph.D., Bayer

Tony Wagner, Ph.D., Jazz Pharmaceuticals

Ilan Wapinski, Ph.D., Sanofi

Michael Weisman, M.D., Cedars-Sinai Medical Center

Mary Wheatley, National Scleroderma Foundation

Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine

Philip Worboys, Ph.D., Sapient Bioanalytics